http://onctalk.com Latest Current Information on Cancer Treatments and Best Practices, Primary Focus on Lung Cancer Sun, 31 Jan 2010 13:44:50 +0000 http://backend.userland.com/rss092 en   I've written a couple of posts on what I'd consider to be the top 10 abstracts in lung cancer at the upcoming ASCO conference that are worth discussing further in lung cancer and that I think are likely to have an impact on lung cancer management over the next few ... http://onctalk.com/2008/05/26/asco-2008-lung-cancer-abstracts-of-note/    There's a new post on a likely important trial in advanced NSCLC that I think will change the standard of care and lead to use of "maintenance" or early second line use of chemo immediately after first line chemo.  The details of the trial and my commentary are in ... http://onctalk.com/2008/05/17/jmen-post/    There's a new post at the GRACE website on the topic of whether oncologists should do molecular testing routinely for NSCLC tumors.  This is the subject of a debate in which I'll be participating in an upcoming meeting.  You can read more about the topic here. http://onctalk.com/2008/05/08/routine-testing-for-egfr-status/   Dr. Laskin wrote a new post on the GRACE site, here, describing in some detail the negative ESCAPE trial of sorafenib with chemo for first line treatment of advanced NSCLC.   Although we're mothballing the OncTalk site and not really adding to it, some people have noted that GRACE doesn't ... http://onctalk.com/2008/05/06/laskin-post-on-grace-lung-site/   The second post of the article on tarceva for advanced BAC, based on a clinical trial from Memorial Sloan Kettering Cancer Center, focuses on biomarkers correlated with better and worse results with tarceva.  This post is available here on the GRACE website. http://onctalk.com/2008/04/30/biomarkers-correlate-with-bac-outcomes-on-tarceva/